Beads (1)Antibody (1)
En ligne (2)
Rabbit (1)Mouse (1)
- (2)
- (1)Acridinium ester Labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HEK293 | Anti-Mouse IgG-Acridinium ester (MALS verified) | ||||||
- | Anti-Mouse IgG-coupled Magnetic Beads (recommended for MPCLIA) |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Belapectin | GR-MD-02 | Phase 3 Clinical | Galectin Therapeutics Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Squamous Cell Carcinoma of Head and Neck; Fibrosis; Hypertension, Portal; Psoriasis; Hepatic Insufficiency; Esophageal and Gastric Varices; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | The University Of Edinburgh, Lund University Foundation | Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19) | Details |
| Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Head and Neck Neoplasms; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Coronaviridae Infections; Colorectal Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Melanoma | Details |
| Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Squamous Cell Carcinoma of Head and Neck; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatic Insufficiency; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ProLectin-M | Phase 2 Clinical | BioXyTran Inc | Cytokine Release Syndrome; Coronavirus Disease 2019 (COVID-19); Influenza, Human | Details | |
| Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Venous Thrombosis; Eye Diseases; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |




